http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
효모 Vector 를 이용한 B 형 간염바이러스 표면 항원 유전자의 Cloning
김경태,송기방,최영철,이상기,한문희 ( K . T . Kim,K . B . Song,Y . C . Choi,S . K . Rhee,M . H . Han ) 생화학분자생물학회 1985 BMB Reports Vol.18 No.2
The structural gene of hepatitis B virus surface antigen (HBsAg) was cloned into a shuttle vector pAAR 6 which is capable of autonomous replication and selection in both of the yeast Saccharomyces cerevisiae and Escherichia coli. This expression vector employs the 5`-flanking region of ADC I gene as a promoter in order for transcribing viral surface antigen coding sequences. After transformation of the recombinant plasmid into yeast strains such as SHY 3, YNN 27, D 13, ATCC 38517 and ATCC 42677, the expression of HBsAg gene in the host cells was evident. The protein synthesized in yeast cells was found to be similar in size, density and shape to the 22 ㎚ particles isolated from the plasma of human hepatitis carriers.
Cloning of the Structural Gene for Hepatitis B Virus Surface Antigen into a Yeast Vector
김경태,송기방,최영철,이상기,한문희,Kim, K.T.,Song, K.B.,Choi, Y.C.,Rhee, S.K.,Han, M.H. 생화학분자생물학회 1985 한국생화학회지 Vol.18 No.2
B형간염 virus의 표면항원(HBsAg) 유전자를 alcohol dehydrogenase (ADCI) 유전자의 promoter를 갖고 있으며 Escherichia coli와 효모인 Saccharomyces cerevisiae에서 자기복제할 수 있는 shuttle vector pAAR 6에 cloning하였다. 표면항원 유전자가 cloning된 재조합 plasmid를 S. cerevisiae SHY 3, YNN 27, D 13, ATCC 38517, ATCC 42677 등의 균주에 형질전환시켜 배양한 후 이들 균주로부터 virus의 표면항원이 생산됨을 방사능 면역측정법으로 확인하였다. 사용한 균주중 YNN 27주에서 가장 많은 표면항원 단백질이 생산되었고 이를 sucrose gradient centrifugation, CsCl density gradient 및 전자현미경으로 조사한 결과 간염환자의 혈청으로부터 분리한 22 nm 크기의 표면항원입자와 형태와 크기면에서 유사한 물질임이 확인되었다. The structural gene of hepatitis B virus surface antigen (HBsAg) was cloned into a shuttle vector pAAR 6 which is capable of autonomous replication and selection in both of the yeast Saccharomyces cerevisiae and Escherichia coli. This expression vector employs the 5'-flanking region of ADC I gene as a promoter in order for transcribing viral surface antigen coding sequences. After transformation of the recombinant plasmid into yeast strains such as SHY 3, YNN 27, D 13, ATCC 38517 and ATCC 42677, the expression of HBsAg gene in the host cells was evident. The protein synthesized in yeast cells was found to be similar in size, density and shape to the 22 nm particles isolated from the plasma of human hepatitis carriers.
Pseudomonas syringas 빙핵활성 단백질 유전자의 크로닝
홍주봉,이혜주,우진경,김정하,함경수,한문희 ( Hog,C . B .,H . J . K . Woo,J . H . Kim,K . S . Hahm,M . H . Han ) 생화학분자생물학회 1990 BMB Reports Vol.23 No.1
A gene codes for a protein with ice-nucleation activity has been cloned from a plant pathogenic strain of Pseudomonas syringae in Korea. Once the gene has been introduced into E. coli, the transformed E. coli showed strong ice-nucleating activities; while the freezing temperatures of the 10 mM phosphate buffer, pH 7.0, with E. coli were from -10℃ to -14℃, E. coli once transformed with pGINP-1 raised the freezing temperature to about -5℃. Restriction enzyme mapping of pGINP-1 showed two Pvu II and two Sal I sites in 4.7 kbp DNA fragment flanked with Bgl II and EcoRI restriction enzyme sites.
Interleukin - 2 와 Cycolphosphamide 를 이용한 말기암 환자 치료
최승훈(S H Choi),임태숙(T S Lim),김병로(B R Kim),박기일(K L Park),이경식(K D Lee),함경수(K S Hahm),나도선(D S Na),한문희(M H Han) 대한소화기학회 1989 대한소화기학회지 Vol.21 No.4
N/A Application of adoptive immunotherapy has been the inability to generate specifically sensitized lymphoid cells with antitumor reactivity. Interleukin-2 is now available in large quantities and has made possible expansion of cells with a diverse spectrum of immune reactivities. In this study, we evaluated the immunologic effects and the response rate of LAK cell, Interleukin-2 and cyclophosphamide administered intravenously in humans with tumors unresponsive to other treatments. There were five hepatomas and a metastatic breast cnacer. Two patients received LAK cell and Interleukin-2 twice. 5.94x10 monounclear cells were obtained in each leukapheresis. Cellular cytotoxicity was measured using 51 Chromium release assay. This study clearly showed that Interleukin-2 and Cyclophosphamide treatment augmented LAK cell activity, but there were no statistically significant differences in the natural killer cell function after the treatment. There were one complete response and one partial response. It could be speculated that LAK, Interleukin-2 and Cyclophosphamide therapy can be used as an adjuvant treatment for the advanced cancer.